Sotera Health Has Completed an Initial Public Offering

November 30, 2020

Sotera Health recently announced the closing of its $1.232 billion initial public offering, which priced on November 19, 2020. The Company’s IPO consisted of 53.6 million shares of common stock (including the over-allotment) sold at $23.00 per share, which was the top of the filing range of $20.00-$23.00. Proceeds will be used primarily to repay debt, for working capital and other general corporate purposes. The shares began trading on The Nasdaq Global Select Market under the symbol “SHC” on November 20, 2020. Sotera is a portfolio company of GTCR and Warburg Pincus.  We served as a co-manager on the transaction.

Sotera Health Company is a leading global provider of mission-critical sterilization and lab testing and advisory services to the medical device and pharmaceutical industries. Sotera provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Sotera gives their customers confidence that the products meet regulatory, safety and effectiveness requirements. With a combined tenure across their businesses of nearly 200 years and their industry-recognized scientific and technological expertise, Sotera helps to ensure the safety of millions of patients and healthcare practitioners around the world every year. Across their 63 facilities worldwide, Sotera has nearly 2,900 employees who are dedicated to safety and quality. Sotera is a trusted partner to more than 5,800 customers in over 50 countries.

For more information, please contact:

John V. Soden

Managing Director
(415) 962-2922